[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-transplant-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-transplant-infection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100568287","liquid-biopsies-for-lung-allograft-damage-classification---leonardo-100568287",false,"NCT06679257","Liquid biopsiEs fOr luNg AllogRaft Damage classificatiOn - LEONARDO","Liquid Biopsies for Lung Allograft Damage Classification","LEONARDO","Inclusion Criteria:\n\n* Luing Transplanted and followed up within the reach of the study paricipating centres.\n\nA good understanding to read and write within the languages in which the consent is provided.\n\nExclusion Criteria:\n\n* Not Lung Transplanted or not followed up within the reach of the study paricipating centres.\n\nNo good understanding to read and write within the languages in which the consent is provided.","ALL","18 Years",{"count":20,"type":21},146,"ESTIMATED","OBSERVATIONAL","LTx has the shortest survival of all solid organ transplants. The complex and time-demanding diagnostics of allograft dysfunction are a significant reason for this.\n\nThe current study aims overarchingly to improve survival after lung transplantation (LTx) through precise and fast diagnostics. The specific aim is to develop direct-to-clinical implementation biomarkers for the most important aspects of long-term survival after LTx. An in-house-developed PCR-based cell-free-DNA methodology (cf-DNA) will be used for allograft damage and combined with specific other biomarkers to identify damage type. The current clinical golden standard for damage identification will be performed at every sampling instance.\n\nThe research will be a single-centre prospective observational cohort study. The control samples at all time points will consist of the samples without allograft damage. Blood will be drawn at fixed time points and clinical events. All analyses will be performed at a separate lab, blinded to the patient's status.\n\n.",[25,26],"Lung Transplant Failure and Rejection","Lung Transplant Infection","RECRUITING","2025-09-15",{"date":30,"type":31},"2025-09-16","ACTUAL",{"date":33,"type":31},"2024-11-15",{"date":35,"type":21},"2030-12",{"name":37,"class":38},"Jesper Magnusson","OTHER_GOV",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":39},"100560937","antimicrobial-therapeutic-drug-monitoring-during-lung-transplant-perioperative-phase-100560937","NCT06583642","Antimicrobial Therapeutic Drug Monitoring During Lung Transplant Perioperative Phase","Inclusion Criteria:\n\n* Recipient of LUTX\n* Age \\> 18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Already undergone LUTX\n* Documented respiratory colonization in the 12 months preceding LUTX\n* Undergoing any antimicrobial therapy preceding LUTX\n* Documented post-LUTX endobronchial plasma leak requiring high levels of PEEP \\> 15 cmH2O.",{"count":47,"type":21},20,"Background: Post-LUTX pneumonia represents a leading cause of death along the first month after LUTX. Donor-derived transmission of pathogenic species occurs up to 25% of recipients receiving a graft with a positive BAL culture, despite in-vitro adequate antimicrobial prophylaxis.\n\nHypothesis: LUTX recipients are either exposed to suboptimal antimicrobial doses or antimicrobial penetration into the lug parenchyma is altered either due to surgery (absence of bronchial anastomoses) or to the hyperinflammatory state.\n\nMethods: LUTX recipients admitted to the intensive care unit at the Fondazione IRCCS Ca' Granda Policlinico Hospital. According to the institutional perioperative prophylaxis protocol and the donor\u002Frecipient ecology the most frequent antimicrobial molecules administered will be: cefepime, vancomycin, and meropenem. Antimicrobial pharmacokinetics will be investigated at three timepoints. Plasma levels of the ongoing antimicrobial molecule will be assessed at ICU admission, on postoperative day 1 and on postoperative day 3. Bronchoalveolar lavage (BAL) samples for the measurement of BAL antimicrobial levels will be collected during the BAL performed for clinical indication on postoperative day 1 and on postoperative day 3.\n\nAbsolute plasma and BAL antimicrobial levels will be assessed. The ratio of BAL to plasma dosage of antimicrobial will be assessed to evaluate antimicrobial penetration within the target tissue. Correlation between both plasma and BAL antimicrobial dosage and recipients' postoperative fluid balance, body weight, vasopressor requirement, renal function will be performed.",[26,50,51],"Pneumonia, Bacterial","Antibiotic Resistant Strain","NOT_YET_RECRUITING","2025-05-19",{"date":55,"type":31},"2025-05-22",{"date":57,"type":21},"2025-07-01",{"date":59,"type":21},"2027-03-01",{"name":61,"class":62},"Policlinico Hospital","OTHER"]